Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2019 Oct 30;18(5):1161–1169.e5. doi: 10.1016/j.cgh.2019.10.036

Table 3.

Sensitivity for each tumor marker for localized PDAC

CA19-9 u/ml All PDAC (n=245) Stage I (n=49)
99th percentile by SNP 60.8% (95% CI: 54.40% to 66.97%) 36.7% (95% CI: 23.42% to 51.71%)
Uniform diagnostic cut-off 46.1 52.7% (46.20% to 59.04%) 28.6% (16.58% to 43.26%)
FUT3 intact only (n=217) 66.4% (59.65% to 72.61%) 40% (25.70% to 55.67%)
CEA ng/ml All PDAC (n=245) Stage I (n=49)
99th percentile by SNP 15.9% (11.57% to 21.11%) 8.2% (2.27% to 19.60%)
Uniform diagnostic cut-off 3.9 13.1% (9.11% to 17.94%) 8.2% (2.27% to 19.60%)
CA125 u/ml All PDAC (n=238) Stage I (n=45)
99th percentile by SNP 17.6% (11.88% to 23.30%) 11.1% (3.71% to 24.05%)
Uniform diagnostic cut-off 19.2 15.5% (11.19% to 20.79%) 11.1% (3.71% to 24.05%)
thrombospondin-2 u/ml n=206 Stage I (n=13)
Uniform diagnostic cut-off 42.2 18% (12.97% to 23.90%) 15.4% (1.92% to 45.45%)